Posts by John

Quotient Sciences introduces an AI-powered platform to optimize drug formulations, accelerating clinical trial timelines and enhancing drug efficacy.

The Health Ministry has mandated strict regulatory compliance for stem cell therapy nationwide to prevent unproven treatments and ensure patient safety.

New clinical trial data suggests CAR-T cell therapy may effectively treat Multiple Sclerosis by resetting the immune system. Learn more about the study.

New trial data confirms long-acting injectable HIV treatments outperform daily oral pills, offering a breakthrough in efficacy for young patients.

The FDA has approved Ultragenyx’s Fayuvi, a groundbreaking gene therapy for a rare neurodegenerative disorder. Discover the impact on patient care.

New study results show Empaveli significantly reduces proteinuria and stabilizes kidney function in adolescents with rare C3G and IC-MPGN.

Quotient Sciences unveils an AI breakthrough in clinical trial design, promising faster drug development and more accurate pharmacokinetic modeling.

New clinical research reveals how regular exercise triggers neurogenesis and improves mood. Learn how physical activity reshapes the brain for better health.

FDA approves Bayer’s Kerendia for kidney disease in Type 1 diabetes, marking the first new treatment option for this patient group in over 30 years.

Virtual biotech firms are deploying thousands of autonomous AI scientist agents to fast-track drug discovery and reduce the costs of medical innovation.